Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | CLPP | Q16740 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489382 | 0.80 | PLA2G7 (0.31) | P2RX7 | |
| SCHEMBL6489420 | 0.76 | GRM4 (0.35) | ADRA1AHRH1ADRA1BGRM4RXFP1 | |
| SCHEMBL6475676 | 0.65 | MEN1 (0.39) | GRM4MAPK14 | |
| SCHEMBL6484781 | 0.64 | PTGER4 (0.41) | RXFP1P2RX7 | |
| SCHEMBL6484092 | 0.64 | MEN1 (0.38) | GRM4MAPK14 | |
| SCHEMBL6490897 | 0.64 | KDM5A (0.38) | ADRA1AHRH1ADRA1BP2RX7 | |
| SCHEMBL6819154 | 0.62 | PTGER4 (0.41) | RXFP1P2RX7 | |
| SCHEMBL6478515 | 0.62 | GRM4 (0.33) | ADRA1AHRH1ADRA1BGRM4P2RX7 | |
| SCHEMBL6489375 | 0.62 | GRM4 (0.33) | ADRA1AHRH1ADRA1BGRM4P2RX7 | |
| SCHEMBL6484250 | 0.61 | FFAR1 (0.33) | GRM4FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | ADRA1A 3956/4885HRH1 1180/4885ADRA1B 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.